<DOC>
	<DOCNO>NCT03068585</DOCNO>
	<brief_summary>In 2010 , complete phase 1 2a clinical trial pCMV-vegf165 patient chronic low limb ischemia ( stage 2a 3 accord Fontaine classification modify A. V. Pokrovsky ) suitable reconstructive surgery endovascular treatment . This study demonstrate safety , feasibility , short-term ( 3 month ) efficacy pCMV-vegf165 gene transfer,12,13which lead conduct phase 2b 3 multicenter clinical trial . The study conduct control Russian Ministry Health complete 2011 . Patients enrol study subject 6-month</brief_summary>
	<brief_title>Efficiency , Safety Portability Neovasculgen</brief_title>
	<detailed_description>We conduct phase 2b/3 multicenter randomize control clinical trial intramuscular transfer plasmid DNA encode vascular endothelial growth factor ( VEGF ) 165 cytomegalovirus promotor ( CMV ) patient atherosclerotic low limb ischemia . A total 100 patient enrol study , , 75 patient randomized test group receive 2 intramuscular injection 1.2 mg pCMV- vegf165 , 14 day apart together standard pharmacological treatment . In , 25 patient randomize control group receive standard treatment . The following end point evaluate within first 6 month study 1.5-year additional follow-up period : pain-free walking distance ( PWD ) , ankle-brachial index ( ABI ) , blood flow velocity ( BFV ) .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>age 40 year ; history stable claudication least 3 month ; stage 2 3 chronic ischemia accord Fontaine classification ( modify A. V. Pokrovsky ) ; presence hemodynamically significant ( stenosis &gt; 70 % and/or occlusion ) diffuse lesion interior ( ) posterior tibial artery ( distal lesion ) ; voluntary inform consent sign dated patient . chronic low limb ischemia nonatherosclerotic genesis ; stage 4 chronic ischemia accord Fontaine classification modify A. V. Pokrovsky ( ischemic ulcer necrotic lesion ) ; severe concomitant pathology life expectancy &lt; 1 year ; infectious disease , history cancer , suspect malignancy ;</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>PAD</keyword>
	<keyword>CLI</keyword>
	<keyword>stage 2a-3 Pokrovsky-Fonteine</keyword>
</DOC>